AbbVie Inc.
ABBV · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $15,776 | $15,423 | $13,343 | $15,102 |
| % Growth | 2.3% | 15.6% | -11.6% | – |
| Cost of Goods Sold | $3,390 | $2,403 | $4,002 | $4,396 |
| Gross Profit | $12,386 | $13,020 | $9,341 | $10,706 |
| % Margin | 78.5% | 84.4% | 70% | 70.9% |
| R&D Expenses | $2,244 | $2,100 | $2,067 | $6,774 |
| G&A Expenses | $0 | $0 | $0 | $779 |
| SG&A Expenses | $3,380 | $3,218 | $3,293 | $2,879 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2,100 |
| Other Operating Expenses | $1,871 | $1,840 | $248 | $2,543 |
| Operating Expenses | $7,495 | $7,158 | $5,608 | $12,196 |
| Operating Income | $4,891 | $5,862 | $3,733 | -$1,490 |
| % Margin | 31% | 38% | 28% | -9.9% |
| Other Income/Exp. Net | -$4,177 | -$4,308 | -$2,072 | -$779 |
| Pre-Tax Income | $714 | $1,554 | $1,661 | -$2,269 |
| Tax Expense | $526 | $613 | $372 | -$2,246 |
| Net Income | $186 | $944 | $1,286 | -$22 |
| % Margin | 1.2% | 6.1% | 9.6% | -0.1% |
| EPS | 0.1 | 0.53 | 0.72 | -0.018 |
| % Growth | -81.1% | -26.4% | 4,077.9% | – |
| EPS Diluted | 0.1 | 0.53 | 0.72 | -0.018 |
| Weighted Avg Shares Out | 1,772 | 1,772 | 1,768 | 1,769 |
| Weighted Avg Shares Out Dil | 1,772 | 1,772 | 1,772 | 1,773 |
| Supplemental Information | – | – | – | – |
| Interest Income | $72 | $62 | $73 | $92 |
| Interest Expense | $781 | $740 | $700 | $702 |
| Depreciation & Amortization | $2,063 | $2,050 | $2,039 | $2,102 |
| EBITDA | $3,444 | $4,344 | $4,400 | $535 |
| % Margin | 21.8% | 28.2% | 33% | 3.5% |